CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 55 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04081337
NCT04081337Phase 1Completed
CompareCT.gov

A Randomized, Placebo-Controlled, Parallel-Arm Study to Investigate the Effect of Once-Weekly Tirzepatide on Energy Expenditure and Food Intake in Obese Subjects

Eli Lilly and Company·interventional·Posted Sep 9, 2019·Updated Feb 8, 2024

In Brief

A Phase 1 clinical trial evaluating Tirzepatide and Placebo for Obesity. Completed, enrolled 55 participants across 1 site.

Detailed Summary

This is a study of tirzepatide in participants with obesity. The main purpose is to learn more about how tirzepatide affects the number of calories participants burn and the amount of food they eat. The study lasted for 28 weeks and will include about 21 visits to the study center.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedSep 9, 2019
Enrollment StartJul 9, 2020
Primary CompletionMay 26, 2022
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 6.8 years ago

Interventions

Tirzepatidedrug

Administered SC

Placebodrug

Administered SC